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аннотация
Специфическое блокирование амплификации аллеля дикого типа в ПЦР с помощью олигонуклеотидов, 
модифицированных по остатку рибозы (закрытые нуклеиновые кислоты, locked nucleic acids, LNA), 
используется для высокочувствительной детекции соматических мутаций в опухолях. Описаны различные 
версии метода анализа мутаций с использованием LNA-олигонуклеотидов как с дополнительной 
модификацией фосфотиоатными группами, так и без таких групп, при этом использовались различные 
дНК полимеразы. В работе проведен анализ оптимальных условий для успешного специфического 
блокирования ПЦР с помощью LNA-олигонуклеотидов при анализе мутаций в генах KRAS и BRAF. Мы 
обнаружили, что фосфотиоатная защита на 5’-конце олигонуклеотидов не влияет на эффективность 
блокирования аллеля дикого типа. Выявлено, что для большинства последовательностей эффективное 
блокирование наблюдается при проведении шага отжига и элонгации ПЦР при температуре на 20–25°С 
ниже температуры плавления LNA-олигонуклеотида. При таких условиях реакции возможна простая и 
высокочувствительная детекция мутаций в генах KRAS и BRAF с использованием как секвенирования 
по Сэнгеру, так и ПЦР в реальном времени с Taqman зондами.
Ключевые слова: запертая нуклеиновая кислота, зажим PCR, мутации, KRAS, bRAF, 
днК-полимераза Taq.
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Abstract
pCR clamping/wild-type blocking pCR with non-extendable locked nucleic acid (LNA) oligonucleotides is used 
for sensitive detection of somatic mutations in tumors. Various versions of the technique use different dNA 
polymerases and LNA oligonucleotides with and without additional phosphorothioate modifications. Here we 
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studied requirements for successful pCR clamping with LNA oligonucleotides and Taq dNA polymerase for 
analysis of mutations in KRAS and BRAF genes by means of real-time pCR and Sanger sequencing. We found 
that addition of phosphorothioate linkages at the 5’-end of LNA oligonucleotide to protect from 5’-exonuclease 
activity of Taq dNA polymerase did not improve clamping. For most target sequences, efficient clamping was 
observed at melting temperature of LNA oligonucleotide 20-25°C above annealing/extension temperature of 
the pCR with a 2-step protocol. Under such conditions, simple and sensitive detection of mutations in KRAS 
and BRAF genes was feasible using real-time pCR with TaqMan probes or Sanger sequencing.
Keywords: locked nucleic acid, PCR clamp, mutations, KRAS, bRAF, Taq DNA polymerase.
Introduction
Activating somatic mutations in certain genes 
(e.g. BRAF, KRAS, EGFR) are used to guide the 
choice of cancer therapy. The large excess of wild-
type DNA often complicates detection of somatic 
mutations in tumor tissue. To detect small amount 
of a mutant allele within a large excess of wild-type 
DNA, a number of methods based on PCR, Sanger 
sequencing, pyrosequencing, mass spectrometry and 
next generation sequencing (NGS) were developed. 
PCR clamping or wild-type blocking (WTB) PCR 
with locked nucleic acid (LNA) oligonucleotide 
can be used for the sensitive detection of somatic 
mutations [1-4]. LNAs are nucleic acids with 2’-
O-4’-C methylene bridge [5]. LNA modifications in an 
oligonucleotide increase melting temperature (Tm) and 
the specificity of binding to the target [5-7]. In WTB 
PCR non-extendable oligonucleotide (PCR clamp) 
corresponding to the wild-type sequence of expected 
mutation is added to PCR. Binding of PCR clamp 
to а target DNA inhibits amplification of the wild-
type allele and results in the selective amplification 
of mutant allele(s) that can be detected by Sanger 
sequencing or by other methods.
It was proposed that clamping oligonucleotide can 
be degraded by the 5’-exonuclease activity of Taq 
DNA polymerase, and for efficient PCR clamping, 
the Stoffel fragment of DNA polymerase without 5’-
exonuclease activity is required [1, 8]. Alternatively, 
some studies used Taq DNA polymerase and LNA 
oligonucleotides protected at the 5’-end with 
phosphorothioate modifications or employed Pfu DNA 
polymerase and its variants without 5’-exonuclease 
activity [9-11]. However, successful PCR clamping 
was also reported with regular Taq DNA polymerase 
and unprotected LNA oligonucleotides [2-4]. Thus, the 
need of PCR clamping to protect the 5’-end of LNA 
oligonucleotide and the need of DNA polymerase 
defective in 5’-exonuclease activity remains obscure. 
Here we studied the requirements for efficient PCR 
clamping with LNA oligonucleotides and Taq DNA 
polymerase for the simple and sensitive detection of 
somatic mutations in tumors.
Materials and Methods
LNA oligonucleotides
We designed PCR clamps KLNA1 (5’-
GCCTACG+C+CA+C+CAGCTCCTT-p-3’ ; 
melting temperature (Tm) 80°C) and KLNA1S 
(5’-GSCSCSTACG+C+CA+C+CAGCTCCTT-p-3’; 
Tm 80°C) corresponding to wild-type anti-sense 
KRAS sequence with codons 12 and 13. The clamps 
had identical nucleotide sequence but KLNA1S 
had phosphorothioate linkages for the first three 
internucleotide bonds at the 5’-end. For BRAF 
sequence including codon V600, we used PCR clamp 
BLNA2 (5’+G+C+T+A+C+A+G+T+G+AGGG-
p-3’; Tm 77°C) [1]. Tm of LNA oligonucleotides 
was calculated by the on-line tool [12]. In the 
oligonucleotides LNA positions are preceded with “+” 
sign, while phosphorothioate linkages are designated 
by “S”. Additionally LNA oligonucleotides carried 
at the 3’-end two or three nucleotide mismatches 
(underlined) and phosphate to block an extension. 
Oligonucleotides were synthesized by «DNK-sintez» 
(Moscow, Russia).
Wild-type and mutant human DNA standards
Recombinant plasmids with mutations KRAS-
G12D (c.35G>A) and BRAF-V600E (c.1799T>A) 
were constructed by site-directed mutagenesis and 
mutations were confirmed by Sanger sequencing. 
Human placenta DNA without KRAS and BRAF 
mutation (Biolink, Russia) was diluted to 2 ng/µl in TE 
buffer (10 mmol/L Tris-HCl, pH 8.0; 1mmol/L EDTA) 
and used as wild-type DNA standard. Concentration of 
wild-type and mutant DNA was determined by real-
time PCR. Wild-type DNA standard was spiked with 
the KRAS-G12D or BRAF-V600E plasmid DNA to 
prepare mutant DNA standards with different ratios of 
mutant/normal allele.
Real-time PCR
Real-time PCR KRAS was done in 25 µl mixture 
containing 1× buffer for Taq DNA polymerase 
(Medigen, Russia), 1.5 mmol/L MgCl2, 0.2 mmol/L 
each of dATP, dGTP, dTTP, dCTP (Medigen, 
Russia), 0.5 µmol/L of forward primer KF1 (5’-
G G C T G G T G G A G TAT T T G ATA G T G T- 3 ’ ) , 
0 . 5  µ m o l / L  r e v e r s e  p r i m e r  K R 1  ( 5 ’ -
GGACAAGATTTACCTCTATTGTTGG-3’) , 
0 . 5  µ m o l / L  Ta q M a n  p r o b e  K T M 6 - 2 
( 5 ’ - F A M - C C T G C ( d T - B H Q 1 )
GAAAATGACTGAATATAAACTTGTGG-p-3’), 
and 1U of SuperHot Taq DNA polymerase (Bioron, 
Germany). SuperHot DNA polymerase is recombinant 
Taq DNA polymerase with anti-Taq Ab for hot-start. PCR 
clamps KLNA1 or KLNA1S were added to 2.0 µmol/L 
when required. Real-time PCR was performed in 
iCycler iQ5 or CFX96 thermocyclers (Bio-Rad) using 
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2-step protocol: 1 cycle 95 ºC for 3 min; followed by 50 
cycles 95 ºC for 15 sec and 55 ºC for 90 sec with optical 
reading at 55 ºC. Difference in Ct values (dCt) in 
reactions with and without PCR clamp was calculated 
as the following: dCt = Ct
+LNA
 – Ct
-LNA
, where Ct
+LNA
 
– is the Ct of the DNA in PCR with clamp, Ct
-LNA
 – is 
the Ct of the DNA in PCR without clamp.
Unless otherwise indicated real-time PCR 
BRAF was done as described for KRAS with 
2-step protocol but using forward primer BF2-2 
(5’- AATGCTTGCTCTGATAGGAAAATG-3’), 
r e v e r s e  p r i m e r  B R 2 - 3  ( 5 ’ -
AGTGGAAAAATAGCCTCAATTCTTA-3’), TaqMan 
probe BTM5-2 (5’-FAM-ATGAAGACC(dT-BHQ1)
CACAGTAAAAATAGGTGATTTTGG-p-3’) and 
PCR clamp BLNA2. When indicated the following 
3-step protocol was used: 1 cycle 95 ºC for 3 min 
followed by 50 cycles 95 ºC for 15 sec, 55 ºC for 30 
sec (with optic reading) and 72 ºC for 20 sec.
Sanger sequencing after PCR clamp
After PCR with clamp oligonucleotide amount of 
DNA may not be sufficient for Sanger sequencing. 
Therefore, DNA was amplified by nested PCR in two 
rounds. In the first round, reaction was done with PCR 
clamp to select for mutant allele essentially as described 
for the real-time PCR with primers KF1, KR1 and PCR 
clamps KLNA1 or KLNA1S without TaqMan probe; 
the following PCR protocol was used: 1 cycle 95 ºC 
for 3 min; followed by 25 cycles 95 ºC for 15 sec and 
55 ºC for 90 sec. Product of the first round was diluted 
1:50 in water and 5µl of diluted DNA was used in the 
second round without PCR clamp to obtain sufficient 
amount of mutation-enriched DNA for Sanger 
sequencing. In the second round, forward primer 
KF2 (5’-GCGTGTATTAACCTTATGTGTGACA-3’) 
a n d  r e v e r s e  p r i m e r  K R 2  ( 5 ’ -
GGCAAGATTTACCTCTATTGTTGGA-3’) were 
used with the following protocol: 1 cycle 95 ºC for 
3 min; followed by 20 cycles 95 ºC for 15 sec, 60 
ºC for 20 sec and 72 ºC for 20 sec. After the second 
round the DNA was purified on AMpure XP magnetic 
beads (Beckman Coulter) and sequenced using 
BigDye1.1 Kit (Applied Biosystems) with KF2 and 
KR2 primers.
Results
Protection of the 5’-end of LNA oligonucleotide is 
not required for efficient PCR clamp with Taq DNA 
polymerase.
We used initially WTB PCR to detect mutations 
at KRAS codons 12 and 13. These two codons have 
sequence GGTGGC with guanine nucleotides being 
mutation hot-spots in different cancers. We used 
sequence of the anti-sense strand of the KRAS gene 
for the clamp design to avoid LNA modification of 
guanine nucleotides that negatively impacts mismatch 
discrimination [6]. We designed clamp oligonucleotides 
KLNA1 and KLNA1S that had identical nucleotide 
sequence but the latter had phosphorothioate linkages 
for the first three internucleotide bonds at the 5’-end to 
protect from digestion by the 5’-exonuclease activity 
of Taq DNA polymerase. We tested both PCR clamps 
for the detection of mutation KRAS-G12D by real-
time PCR and Sanger sequencing.
In real-time PCR both PCR clamps inhibited 
amplification of WT human KRAS DNA as evidenced 
by large increase in Ct (Figure 1A). As a quantitative 
parameter of performance of a PCR clamp we used 
Figure 1. detection of KRAS mutation G12d using Taq dNA polymerase and different pCR clamps. Ten nanogram human placenta dNA 
with wild-type KRAS or the same dNA spiked with 1% or 5% dNA copies KRAS-G12d was tested. pCR was done with and without 
pCR clamp KLNA1 without phosphorothioate linkages, or KLNA1S with phosphorothioate linkages. A, B - real-time pCR, plot of Ct and 
dCt, accordingly. C- F - Sanger sequencing after pCR without clamps (C, d) or with clamps KLNA1 (E) or KLNA1S (F). Codon 12 is 
underlined, nucleotide position corresponding to wild-type and mutation p.G12d (c.35G>A) is indicated by an arrow
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Figure 2. performance of pCR clamp at different annealing/
extension temperatures (Tann/ext). Real-time pCR of 5% KRAS-
G12d and wild-type dNA with and without pCR clamp KLNA1. 
pCR was done using 2-step protocol with Tann/ext at 54.6; 60.2; 
or 62.8°C. difference of Ct for reactions with and without clamp 
(dCt) and linear approximation of dCt is shown for 5% KRAS-
G12d (solid line) and wild-type dNA (broken line)
the difference in Ct values (dCt) in reactions with and 
without PCR clamp. DNA samples spiked with KRAS-
G12D plasmid had smaller dCt compared to wild-type, 
so that 1% mutant allele was readily distinguished 
(Figure 1B). Importantly, Ct as well as dCt values 
were similar in PCR with either clamp indicating 
similar performance of LNA oligonucleotides with 
and without phosphorothioate linkages.
Sanger sequencing of amplicons after PCR with 
either oligonucleotide clamp showed similar detection 
of 1% mutant allele (Figure 1D, F). Of note, 5% mutant 
allele was not visible by Sanger sequencing without 
PCR clamp (Figure 1E) and reliable detection required 
20% or more mutant allele (data not shown).
These real-time PCR and Sanger sequencing 
data indicated that protection from 5’-exonuclease 
activity of Taq DNA polymerase did not improve PCR 
clamping by LNA oligonucleotides.
Efficient PCR block is observed at an annealing/
extension temperature of 20-25 degrees below 
calculated Tm of the PCR clamp.
The strength of oligonucleotide binding to the 
template, and consequently efficiency of clamping 
should increase with higher Tm of LNA oligonucleotide 
and lower annealing/extension temperature (Tann/ext) 
during PCR. We investigated optimal Tann/ext for a 
PCR clamp with certain calculated Tm. Increase in 
Tann/ext from 54.6 to 62.8°C resulted in decrease in 
dCt of the wild-type DNA, while dCt of DNA with 
5% allele KRAS-G12D was not appreciably changed 
(Figure 2). These data indicated less efficient PCR 
clamp and drop in discriminating power between 
wild-type and mutant alleles with increased Tann/
ext. Further increase of Tann/ext to 65°C resulted 
in poor PCR performance, which was manifested in 
drop in fluorescence and large increase in Ct (data 
not shown).
Two-step PCR protocol is preferred for effective 
clamping.
Different studies use LNA-based PCR clamps 
either in 2-step PCR with 60-65°C annealing/
extension temperature [2, 3, 10] or in classic 3-step 
PCR protocol with 56-64°C annealing and 72°C 
extension temperature [1, 4, 9, 11]. We speculated 
Figure 3. detection of BRAF mutation V600E by pCR clamping using 2-step and 3-step protocol. Real-time pCR BRAF using 2-step 
protocol with Tann/ext 55°C (A), or 3-step protocol with 55°C annealing and 72°C extension (B). Ct of wild-type dNA and 1% or 5% 
BRAF-V600E is shown in reactions with and without pCR clamp BLNA2
that extension at 72°C can cause weaker binding of 
LNA oligonucleotide to the target and compromise 
clamping. Importantly, we described PCR clamp for 
BRAF-V600 that did not block amplification of the 
wild-type DNA in 3-step PCR protocol with Taq DNA 
polymerase [1]. We tested this PCR clamp in 2-step and 
3-step PCR protocols. The amplification of wild type 
DNA was effectively blocked by PCR clamp that was 
manifested in large increase in Ct of the DNA if 2-step 
PCR protocol was applied with 55°C Tann/ext. Under 
such conditions DNA spiked with 1% BRAF-V600E 
allele was readily detected (Figure 3A). However, in 
agreement with Dominguez and Kolodney [1] the 
clamp did not block PCR with Taq DNA polymerase 
in 3-step PCR protocol (Figure 3B). These data showed 
that 2-step PCR protocol with 55 ºC Tann/ext was 
preferred for efficient clamping.
Furthermore, we designed and tested additional 
LNA oligonucleotides as PCR clamps to different 
loci in EGFR, KRAS and NRAS genes (data not 
shown). PCR was done using 2-step protocol with 
55°C annealing temperature. We found that LNA 
oligonucleotides with Tm 72-73°C were poor blockers; 
in contrast, PCR was efficiently blocked by LNA 
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oligonucleotides that had Tm about 80°C (range 
76-80°C). The only exception was PCR clamp for 
sequence of NRAS including codons 12 and 13. In this 
case LNA oligonucleotide with Tm 80°C did not block 
PCR. Importantly, another oligonucleotide for the same 
sequence with additional LNA positions that increased 
Tm to 92°C blocked PCR of wild-type NRAS DNA 
and allowed detection of 1% NRAS-G12D (data not 
shown). Taken together these data indicated that for 
efficient clamping the Tm of oligonucleotide clamp 
should be at least 20°C above Tann/ext.
Discussion
WTB PCR using LNA oligonucleotides is a 
simple sensitive method for the detection of somatic 
mutations in tumors. Nafa et al. [13] reviewed the 
method; however, several important parameters of the 
technique remained unclear. In this study we evaluated 
requirements for effective PCR clamping by LNA 
oligonucleotides.
We found that phosphorothioate linkages in LNA 
oligonucleotide did not improve PCR clamping, 
indicating that protection of the clamp from 5’-
exonuclease activity of the Taq DNA polymerase was 
not required. Interestingly, Stoffel fragment that lacks 
5’-3’ exonuclease activity was much more sensitive to 
PCR clamp in comparison to Taq DNA polymerase [1]. 
Our observation that phosphorothioate modifications 
of LNA oligonucleotide did not improve clamping 
indicated that the 5’-exonuclease activity of Taq DNA 
polymerase was not likely the reason for difference 
in sensitivity of these enzymes to PCR clamp. Most 
plausible explanation is weaker binding to the DNA 
template of Stoffel fragment in comparison to Taq 
DNA polymerase, which is manifested in about 10-fold 
difference in the binding constants of these enzymes 
to the DNA [14].
Tm of LNA oligonucleotide and annealing/extension 
temperature during PCR were critical parameters that 
had strong impact on clamping. There was a poor 
clamping if Tm of LNA oligonucleotide was 20°C 
lower than the annealing/extension temperature of the 
PCR. This observation provides simple and efficient 
rationale for design and optimization of WTB PCR 
with PCR clamps based on LNA oligonucleotides. 
Software to determine Tm of LNA oligonucleotides 
is available at the IDT and the Exiqon company sites 
[12, 15]. However, we noted that for different LNA 
oligonucleotides, the calculated Tm was 2.5-19.5°C 
lower using IDT software compared to the Exiqon 
one. We used Exiqon tool, however calculated Tm 
using either program should be used with caution for 
predicting real Tm for the design of PCR protocol. We 
think that poor clamping by some LNA oligonucleotides 
with the calculated Tm of about 80°C was the result of 
an error in the calculated Tm. In all cases when LNA 
oligonucleotide was not blocking PCR, adding more 
LNA positions to increase Tm incrementally by 5-12°C 
was sufficient for the effective PCR clamping.
Gel-electrophoresis, Sanger sequencing or real-
time PCR can be used to evaluate performance of a 
PCR clamp. However, in our hands impact of PCR 
clamp on intensity of PCR bands sometimes was 
not clearly visible after gel-electrophoresis of PCR 
products. Importantly, real-time PCR and Sanger 
sequencing were in agreement with each other and 
provided more accurate estimate of performance of 
a PCR clamp.
Both real-time PCR and Sanger sequencing can 
be used to detect mutations by PCR clamping. In 
comparison to Sanger sequencing, real-time PCR 
had faster turnaround time and was less expensive, 
however exact genotyping was not possible. A 
limitation of Sanger sequencing after PCR clamping 
were occasional mutation artifacts on wild-type 
DNA. The problem was previously reported [4, 10] 
and is believed to result from mistakes of Taq DNA 
polymerase. The problem can be solved by the use of 
DNA polymerase with proofreading activity instead 
of Taq DNA polymerase [10]. Other potential options 
are a hi-fidelity version of Taq DNA polymerase [16], 
or use of less PCR cycles with PCR clamp.
In conclusion, our data showed efficient PCR 
clamping by LNA oligonucleotides with calculated 
Tm of at least 20°C above the annealing/extension 
temperature in a 2-step PCR protocol. Enrichment 
for target mutations was confirmed by the Sanger 
sequencing of PCR products. Importantly, Taq DNA 
polymerase and LNA oligonucleotides without 
phosphorothioate modifications were used without 
compromise in the efficiency of PCR clamp. This allows 
rational design of inexpensive, simple and sensitive 
assays for clinically actionable mutations in convenient 
format of real-time PCR with TaqMan probes.
ЛИТЕРАТУРА/REFERENCES
1. Dominguez P.L., Kolodney M.S. Wild-type blocking polymerase 
chain reaction for detection of single nucleotide minority mutations from 
clinical specimens. Oncogene. 2005 Oct 13; 24(45): 6830–4. doi: 10.1038/
sj.onc.1208832.
2. Sidon P., Heimann P., Lambert F., Dessars B., Robin V., 
El Housni H. Combined locked nucleic acid and molecular beacon tech-
nologies for sensitive detection of the JAK2V617F somatic single-base 
sequence variant. Clin Chem. 2006; 52(7): 1436–1438. doi: 10.1373/
clinchem.2006.066886.
3. Thiede C., Creutzig E., Illmer T., Schaich M., Heise V., Ehninger G., 
Landt O. Rapid and sensitive typing of NPM1 mutations using LNA-
mediated PCR clamping. Leukemia. 2006; 20(10): 1897–1899. doi: 
10.1038/sj.leu.2404367.
4. Arcila M., Lau C., Nafa K., Ladanyi M. Detection of KRAS 
and BRAF mutations in colorectal carcinoma roles for high-sensitivity 
locked nucleic acid-PCR sequencing and broad-spectrum mass spectrom-
etry genotyping. J Mol Diagn. 2011 Jan; 13(1): 64–73. doi: 10.1016/j.
jmoldx.2010.11.005.
5. Koshkin A.A., Singh S.K., Nielsen P., Rajwanshi V.K., Kumar R., 
Meldgaard M., Wengel J. LNA (Locked Nucleic Acids): Synthesis of the 
adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclo-
nucleoside monomers, oligomerisation, and unprecedented nucleic acid 
recognition. Tetrahedron. 1998; 54(14): 3607–3630.
6. You Y., Moreira B.G., Behlke M.A., Owczarzy R. Design of LNA 
probes that improve mismatch discrimination. Nucleic Acids Res. 2006; 
34(8): e60. doi: 10.1093/nar/gkl175.
35СИБИРСКИЙ ОНКОЛОГИЧЕСКИЙ ЖУРНАЛ. 2018; 17(4): 30–35
лаБораторные и эКспериментальные исследоВаниЯ
7. Owczarzy R., You Y., Groth C.L., Tataurov A.V. Stability and mis-
match discrimination of locked nucleic acid-DNA duplexes. Biochemistry. 
2011; 50(43): 9352–9367. doi: 10.1021/bi200904e.
8. Yu D., Mukai M., Liu Q., Steinman C.R. Specific inhibition of PCR 
by non-extendable oligonucleotides using a 5’ to 3’ exonuclease-deficient 
DNA polymerase. Biotechniques. 1997; 23(4): 714–716, 718–720.
9. Laughlin T.S., Becker M.W., Liesveld J.L., Mulford D.A., Abboud C.N., 
Brown P., Rothberg P.G. Rapid method for detection of mutations in the 
nucleophosmin gene in acute myeloid leukemia. J Mol Diagn. 2008 Jul; 
10(4): 338–45. doi: 10.2353/jmoldx.2008.070175.
10. Laughlin T.S., Moliterno A.R., Stein B.L., Rothberg P.G. Detection 
of exon 12 Mutations in the JAK2 gene: enhanced analytical sensitivity 
using clamped PCR and nucleotide sequencing. J Mol Diagn. 2010 May; 
12(3): 278–82. doi: 10.2353/jmoldx.2010.090177.
11. Huang Q., Wang G.Y., Huang J.F., Zhang B., Fu W.L. High sensi-
tive mutation analysis on KRAS gene using LNA/DNA chimeras as PCR 
amplification blockers of wild-type alleles. Mol Cell Probes. 2010; 24(6): 
376–380. doi: 10.1016/j.mcp.2010.07.010.
12 Exiqon [Internet]. URL: https://www.exiqon.com/oligo-tools (cited 
25 June 2018).
13. Nafa K., Hameed M., Arcila M.E. Locked Nucleic Acid Probes 
(LNA) for Enhanced Detection of Low-Level, Clinically Significant 
Mutations. Methods Mol Biol. 2016; 1392: 71–82. doi: 10.1007/978-1-
4939-3360-0_8.
14. Pavlov A.R., Pavlova N.V., Kozyavkin S.A., Slesarev A.I. Coopera-
tion between catalytic and DNA binding domains enhances thermostability 
and supports DNA synthesis at higher temperatures by thermostable DNA 
polymerases. Biochemistry. 2012 Mar 13; 51(10): 2032–43. doi: 10.1021/
bi2014807.
15. OligoAnalyzer 3.1. [Internet]. URL: http://eu.idtdna.com/calc/
analyzer. (cited 25 June 2018).
16. Stadler J., Eder J., Pratscher B., Brandt S., Schneller D., Mülleg-
ger R., Vogl C., Trautinger F., Brem G., Burgstaller J.P. SNPase-ARMS 
qPCR: Ultrasensitive Mutation-Based Detection of Cell-Free Tumor DNA 
in Melanoma Patients. PLoS One. 2015 Nov 12; 10(11): e0142273. doi: 
10.1371/journal.pone.0142273.
Received 29.06.18
Accepted 27.07.18
Funding
The study was supported by the Russian Science Foundation (15-14-10004 project).
Conflict of interest
V.A. Shamanin and S.P. Kovalenko owe shares of the Biolink Ltd.
Other authors declare that they have no conflict of interest.
AbOuT THE AuTHORS
Vladimir A. Shamanin, PhD, Senior Researcher, Federal Research Center of Fundamental and Translational Medicine (Novosibirsk, 
Russia). E-mail: vladimir.shamanin@gmail.com. 
Igor V. Karpov, laboratory assistant, Federal Research Center of Fundamental and Translational Medicine (Novosibirsk, Russia). 
E-mail: karp_na@mail.ru.
Еkaterina E. Pisareva, PhD, Senior Researcher, Federal Research Center of Fundamental and Translational Medicine (Novosibirsk, 
Russia). E-mail: katerina.pisareva@mail.ru.
Nadezhda I. Gutkina, PhD, Senior Researcher, Federal Research Center of Fundamental and Translational Medicine (Novosibirsk, 
Russia). E-mail: gutkina.nadezhda@gmail.com.
Sergey P. Kovalenko, DSc, Head of Laboratory, Federal Research Center of Fundamental and Translational Medicine (Novosibirsk, 
Russia). E-mail: sp_kovalenko@yahoo.com.
сВедениЯ оБ аВтораХ
Шаманин Владимир Александрович, кандидат биологических наук, старший научный сотрудник, Федеральный исследо-
вательский центр фундаментальной и трансляционной медицины (г. Новосибирск, Россия). E-mail: vladimir.shamanin@gmail.
com. SPIN-код: 5669-0201. AuthorID: 477135.
Карпов Игорь Владимирович, лаборант, Федеральный исследовательский центр фундаментальной и трансляционной меди-
цины (г. Новосибирск, Россия). E-mail: karp_na@mail.ru.
Писарева Екатерина Евгеньевна, кандидат биологических наук, научный сотрудник, Федеральный исследовательский центр 
фундаментальной и трансляционной медицины (г. Новосибирск, Россия). E-mail: katerina.pisareva@mail.ru. SPIN-код: 7151-
5842. AuthorID: 795623.
Гуткина Надежда Игоревна, кандидат биологических наук, старший научный сотрудник, Федеральный исследовательский 
центр фундаментальной и трансляционной медицины (г. Новосибирск, Россия). E-mail: gutkina.nadezhda@gmail.com. SPIN-код: 
6170-9570. AuthorID: 98026.
Коваленко Сергей Петрович, доктор биологических наук, руководитель лаборатории, Федеральный исследовательский 
центр фундаментальной и трансляционной медицины (г. Новосибирск, Россия). E-mail: sp_kovalenko@yahoo.com. SPIN-код: 
2272-6747. AuthorID: 92420.
Финансирование
Исследование было поддержано грантом Российского научного фонда 15-14-10004.
Конфликт интересов
В.А. Шаманин и С.П. Коваленко представляют интересы компании ООО «Биолинк».
Остальные авторы объявляют, что у них нет конфликта интересов.
Поступила 29.06.18
Принята в печать 27.07.18
